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Abstract—Using ELISA analysis, rat C5a was stimulated in serum from rats
undergoing systemic activation of complement after intravenous infusion of purified
cobra venom factor (CVF). Biological (neutrophil chemotactic) activity was also
assessed. Serum levels of C5a were directly proportional to the amount of CVF
infused. C5a and neutrophil chemotactic activity, peaked by 5 min, then plateaued.
In vitro addition of anti-C5a to serum samples of CVF-infused rats totally abolished
chemotactic activity, indicating that all biological activity could be ascribed to
C5a. Blood neutrophils obtained from CVF-infused animals showed a significant
upregulation of CDllb, the increase being reduced (38%) in animals pretreated with
anti-C5a. These findings indicate that infusion of CVF into rats produces generation
of C5a, all chemotactic activity in serum being related to C5a. The in vivo generation
of C5a is, at least inpart, responsible for upregulation of CD11b on blood neutrophils.
INTRODUCTION
Cobra venom factor (CVF) is one of several components found in cobra venom
from Naja naja. CVF has properties similar to the activation product of the third
component (C3) of human complement, C3b (1-6). CVF binds in the presence
of Mg++ to factor B, forming a complex (CVF • B). This complex is cleaved
into CVF • Bb and Ba by factor D. CVF • Bb acts as a C3 and C5 conver-
tase and is very stable, with a serum half-life of 7 hr at 37°C, as compared to
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C3b • Bb, which dissociates with a half-life of 1.5 min (7). This implies that
injection of sufficient doses of CVF into animals leads to extensive complement
activation, resulting in complement-depletion (8). In the course of the comple-
ment activation cascade, C3 and C5-convertase activity leads to formation of the
anaphylatoxins, C3a and C5a (7,9). C5a, a 14 kDa glycoprotein has been known
to have potent proinflammatory functions that may be important in leukocyte
recruitment (7-11).
Intravascular generation of C5a by infusion of CVF produces neutrophil-
dependent lung vascular injury by activating neutrophils, causing accumulation
of neutrophils in the lung vasculature and leading to neutropenia, followed by
granulocytosis and increasing lung vascular permeability with injury of endo-
thelial cells, intraalveolar hemorrhage, fibrin deposition and interstitial edema
(8,12). Recently it has been shown that neutralization of C5a in the CVF model
of acute lung injury with anti-C5a IgG could reduce secondary lung injury by
95% and reduce lung MPO-content by 39% in the rat, indicating that C5a plays
a key role in neutrophil activation and secondary lung injury (11). Prior to this
report, no technology was available for direct measurement of rat C5a after in
vitro or in vivo activation of complement in rats. In the present study we mea-
sured C5a levels in rat serum as well as serum-chemotactic activity after com-
plement activation by CVF. The data provide quantitative assessments of serum
levels of C5a as well as amounts of neutrophil chemotactic activity. They also
indicate that CVF-induced upregulation of CD 11b on neutrophils is, at least in
part, C5a-dependent.
MATERIALS AND METHODS
Reagents. Unless otherwise specified, all reagents were purchased from Sigma Co. St. Louis,
Missouri).
Anti-C5a. Rabbits were repeatedly immunized with purified rat C5a to obtain a polyclonal
IgG antibody (7). The antibody was shown in recent studies (11) to block neutrophil chemotactic
activity in activated rat serum as well as chemotactic activity associated with purified rat C5a but not
to block total complement activity (CH50) in whole rate serum (11). The IgG fraction was purified
over a 1.5 x 12 cm chromatography column (Bio Rad Laboratories, Hercules, California) made with
2.5 ml of protein G. The column was extensively washed with DPBS pH 7.5, the serum diluted 1:2
with DPBS and applied in 4 ml portions. The column was drained and washed extensively until
absorbance readings at 280 nm were below an optical density of 0.02. The IgG fraction was eluted
with 0.1 M glycine pH 2.5 into tubes containing 1 M tris pH 8.8. The eluates were dialyzed four
times against DPBS (pH 7.5) and finally concentrated using Centricon 100 devices (Amicon Inc.,
Beverly, Massachusetts) to final concentrations of 5 mg/ml. Reactivity of the purified antibody with
purified C5a was shown in Western blot analysis (11).
Placement of Intra-arterial Catheters and Animal Model of CVF-lnduced Lung Injury. Male
Long Evans rats (275-300 g, Charles River Laboratories, Portage, Michigan) were anesthetized
with ketamine hydrochloride (80 mg/kg, Parke Davis and Co., Morris Plains, New Jersey) and
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Xylazine hydrochloride (8 mg/kg, Lloyd Laboratories, Shenandoah, Iowa). Intra-arterial carotid
PE-50 catheters (Becton-Dickinson Co., Sparks, Maryland) were placed 24 hr prior to the CVF-
experiment by a longitudinal incision over the anterior cervical area, separating the left carotid artery
underneath the sternocleidomastoideus muscle from the vagal nerve, followed by temporary ligature
oif the distal carotid artery and placement and fixation of the catheter in the artery. The catheters were
then threaded subcutaneously into the neck, externalized, rolled up and fixed with a tape in order to
al low the animals to move freely. The animals were allowed to eat and drink and were used for the
CVF experiment on the following day. Cobra venom factor was isolated from lyophilized Naja naja
venom (ALI corporation, Ann Arbor, Michigan) by ion exchange and gel nitration chromatography
(1,8). The animals were anesthetized as described above. Four hundred ul blood were drawn on
ice at following time-points: before CVF injection, 1, 2, 5, 10, 15, 20, 25 and 30 min after intra-
venous CVF injection. After 30 min the animals were sacrificed. Serum was separated and frozen
at -80°C.
C5a EL/SA. Microtitration plates (Immulon 4, Dynatech Laboratories, Inc., Chantilly, Vir-
ginia) were coated with anti-rat C5a at a concentration of 5 ug/ml, incubated overnight and washed
three times thereafter. During all subsequent procedural steps, incubation time was 1 hr at 37°C
followed by washing of the plate with PBS containing 0.05% Tween-20. Blocking of non-specific
binding sites was obtained with 1% milk. Seventy-five ul of the serum samples diluted 1:100 to
1:200 in dilution buffer containing milk as well as a rat C5a standard, with concentrations ranging
from 0.049 ng/ml to 100 ng/ml. Ninety n\ of biotinylated anti-C5a was used at a concentration of
500 ng/ml and 100 ul of a 1:3000 dilution of streptavidin horseradish peroxidase (Zymed, S. San
Francisco, California). Finally, 200 nl peroxidase substrate (o-phenylendiamin hydrochloride) was
added. Color development was stopped by adding 3 M h^SCX) and the absorbance read at 490 nm
using a plate reader.
Neutrophil Chemotaxis Assay. Blood was drawn from normal humans into vials contain-
ing citrate [Anticoagulant Citrate Dextrose Solution USP (ACD) Formula A, Baxter Corp., Deer-
field, Illinois]. Neutrophils were isolated by Ficoll and Dextran sedimentation (Pharmacia Biotech,
ABN, Uppsala, Sweden). Remaining red blood cells were lysed with water. The neutrophils were
washed several times with DPBS (with Ca++ and Mg++) containing 0.1% BSA (endotoxin free)
and fluorescein-labeled with BCECF-AM (Molecular Probes, Inc., Eugene, Oregon). The cells were
washed again and resuspended in Hank's balanced salt solution with 0.1% endotoxin free BSA to a
final concentration of 5 x 106 cells/ml. The bottom part of the chemotaxis chamber (Neuro Probe
Inc., Cabin John, Maryland) was loaded with 30 ul of the 1:100 serum dilutions in HBSS per well.
Formyl-Met-Leu-Phe (FMLP) at concentrations of 10~3 to 10~9 M was used as a standard chemo-
attractant. 44 ul of the cell suspension were applied to each well of the top part of the chamber to
which a polycarbonate filter with a pore size of 3 nm was attached. The chamber was incubated
30 min at 37°C. Fluorescence was measured in a cytofluorometer (Cytofiuor Model 2300, Millipore
Corp., Bedford, Massachusetts).
Flow Cytomelric Analysis of Neutrophils. Neutrophils (1 x 105), isolated from rat blood,
were stained using 5 ug/ml monoclonal antibody to CD11b (lB6c) or an isotope-matched control,
(MOPC-21) followed by fluorescence-conjugated goat anti-mouse IgG antibodies (AMAC, West-
brook, Maine) and subsequent fixation in 2% paraformaldehyde solution (13). Neutrophil popula-
tions (identified by forward versus right-angle light scatter characteristics) were measured on an
FACScan (Becton Dickinson, San Jose, California) in which 10,000 cells per gated determination
were counted. Extent of fluorescence intensity (mean channel fluorescence) was analyzed using PC-
Lysis software (Becton-Dickinson, San Jose, California).
Statistical Analysis. Data were expressed as mean plus/minus the standard error of the mean
(SEM). A paired t-test was employed to compare the response between two treatments. Two-way
analysis of variance in combination with Dunnett's multiple comparisons test was used to determine
the significance of differences between controls and multiple experimental groups. Statistical signif-
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icance was defined as p < 0.05. Specifics regarding details of experiments are contained in the text
or in the figure legends.
RESULTS
Relationship Between CVF Amounts and Serum C5a Levels. In rats,
receiving intravenous injections of 2, 4, 6 or 8 units of CVF (or saline in trie
negative group), C5a levels were measured at 5 min. There was a clear dose-
response relationship between amounts of CVF infused and C5a generation, with
a plateau appearing at 6-8 units CVF (Figure 1). The C5a values for the salin<;-
infused rats and rats infused with 2, 4, 6 or 8 units of CVF were: 4 ± 1, 531 ±
83, 835 + 45, 1548 + 236 and 1203 ± 242 ng C5a/, respectively.
In Vivo Suppression of Serum Activities by Anti-C5a. Serum samples were
obtained from rats at times 0, 1, 2, 5, 10, 15, 20, 25 and 30 min after intravenous
infusion of 4 units CVF. Rats were either pretreated intravenously with 300 ug
normal rabbit IgG or anti-rat C5a. C5a content (as determined by ELISA) and
neutrophil chemotactic activity were measured. The data are shown in Figure
2. C5a content in serum peaked within the first 2 min, plateauing through the
10 min interval, and then declining (Figure 2A). Chemotactic activity reached
a peak within the first 10 min, followed by a slight decline thereafter (Figure
2B). As will be shown in this and in Figure 3, precise profiles of serum con-
Fig. 1. Serum levels of C5a, as assessed by ELISA, as a function of CVF dose infused into rats.
For each data point, N = 3.
Chemotactic Activity Following Systemic Activation of Complement 329
Fig. 2. Time-course for C5a serum levels (frame A) and serum chemotactic activity (frame B) fol-
lowing injection of 4 units of CVF into rats pretreated with 300 ug normal rabbit IgG or 300 ug
anti-rat C5a. Serum samples were obtained at 5 min after injection of CVF. For each time point,
N = 3.
tent of C5a and chemotactic activity vary slightly from experimental group to
experimental group, but the overall profiles are quite similar. When animals were
pretreated intravenously with 300 ug anti-C5a, the subsequent injection of CVF
resulted in no detectable decline in C5a or chemotactic activity in serum during
the first 1-2 min, but, thereafter there were significant reductions in both C5a and
in chemotactic activity in serum from animals treated with anti-C5a (Figure 2,
A, B).
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In Vitro Blocking Effects of Anti-C5a on Chemotactic Activity. Five sets of
animals (N = 4 for each group) were evaluated for effects on C5a and on chemo-
tactic activity following in vitro addition of anti-C5a to serum samples obtained
at various time points after infusion in vivo of CVF. The data are shown in Fig-
ure 3. The prompt appearance (within 2 min) and plateauing (between 5 and
30 min) of C5a (frame A) and chemotactic activity (frame B) in serum samples
was documented. Addition of 50 ng anti-rat C5a rabbit IgG (to 1.0 ml serum)
resulted in complete abolition of chemotactic activity (frame B), indicating that
all chemotactic activity could be ascribed to C5a.
Fig. 3. Time course in appearance of C5a (frame A) and neutrophil chemotactic activity (frame
B) in serum of rats injected with 4 units of CVF. Samples were obtained via indwelling arterial
catheters. Both antigenic and biological activities in serum could be totally suppressed by in vitro
addition to serum of anti-C5a (50 ug/ml). For each measurement, N = 3.
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Flow Cytometric Analysis of CD11b in Blood Neutrophils. Blood samples
were obtained from rats receiving 4 units CVF intravenously. The neutrophil con-
tent of CD11b was evaluated on the basis of flow cytometric analysis at various
time points after infusion of CVF. The results are shown in Table 1. Early time
points (e.g. 1-10 min) were not analyzed because of the profound neutropenia
occurring in animals infused with CVF, making retrieval of adequate numbers of
blood neutrophils for reliable analysis difficult. At 15 min, neutrophil content of
CDllb was approximately doubled (P=0.02) in CVF-infused rats; anti-C5a treat-
ment of rats caused a modest reduction (approximately 31 %) in CD 11 b content, but
this did not reach statistical significance. At 30 min, CD11b content on blood neu-
trophils was increased by 3.4 fold and, in the in vivo presence of anti-C5a, the level
of CDllb fell by approximately 38% (p = 0.03) (Table 1). Accordingly, upregula-
ti on of CD 11 b on blood neutrophils after intravenous infusion of CVF can, at least
in part, be attributed to C5a. To what extent other factors, such as C5b-9 may be
involved, remains to be determined. It should also be noted that probably an even
more pronounced upregulation of CD11b might occur on neutrophils that have
lodged in the lung microvasculature.
DISCUSSION
Activation of the alternative pathway of complement activation is consid-
ered to be an effective defense mechanism against invading microorganisms (6).
However, excessive activation may lead to harmful amounts of two potent acti-
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vation products, C5a and the membrane attack complex, C5b-9. CVF has long
been known to be a potent complement activator that leads to extensive in vivo
activation of complement. To our knowledge, no data on levels of C5a generated
in vivo are available. CVF is a 140 kDa protein consisting of 3 subunits A, B and
C, with molecular weights of approximately 72, 54 and 27-35 kDa, respectively
(2). In earlier studies, C5a levels could only be estimated indirectly by measuring
neutrophil chemotactic activity in serum from CVF-treated animals (8). The pre-
cise contribution to chemotactic activity by C5a was undetermined. By ELISA
technique, we have been able to measure C5a presence directly in serum. In the
current experiments, the appearance of serum chemotactic activity was parallel to
the C5a concentration in serum, leading to the conclusion that, at least within the
first thirty minutes after complement activation, C5a is probably the only relevant
neutrophil chemoattractant generated. It seems likely that, in CVF-induced lung
injury, which is neutrophil-dependent (8), C5a is a key mediator that initiates the
chain of events leading to lung vascular injury. One possible mechanism leading
to injury might be through the interaction of C5a with lung vascular endothelial
cells, causing P-selectin (but not ICAM-1) upregulation (14). In this model of
injury, endothelial P-selectin is required for adhesion of neutrophils and subse-
quent damage to the vascular endothelium produced by oxidants generated from
activated neutrophils (8,12,15). In vitro, it has been shown that C5a can induce
human umbilical vein endothelial cells to express P-selectin (16). It seems likely
that neutrophils form intravascular aggregates, which are induced by C5a. Such
events would also cause increased expression of Mac-1 (CD11b/CD 18) on the
surface of neutrophils as well as oxidant production. The ability of anti-C5a to
attenuate, at least in part, these reactions seems likely to be linked to these acti-
vation steps. Why only partial reduction by anti-C5a in upregulation of CD11b
was found, remains to be explained. The lack of complete suppression might be
related to massive levels of C5a generated by infusion of CVF. It is also pos-
sible that additional products of the complement system, such as C5b-9, may
contribute to upregulation of neutrophil CD11b. This possibility remains to be
determined.
The inability of anti-C5a to abolish the rapid increase in C5a within the
first two min after CVF injection (Figure 3) is likely due to the overwhelm-
ing production of C5a immediately after infusion of CVF. The ability of anti-
C5a to suppress completely the presence of chemotactic activity in serum from
CVF-infused rats indicates that this activity can be completely attributed to the
presence of C5a.
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